New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
04:55 EDTPEP, PEP, F, F, PRGO, PRGO, ROC, ROC, SYMC, SYMC, MS, MS, FRX, FRX, TWC, TWC, JNPR, JNPR, HD, HD, GILD, GILD, CSCO, CSCO, SI, SIWall Street Journal to hold annual meeting
Wall Street Journal CFO Network Annual Meeting to be held in Washington, D.C. on June 16-17.
News For PEP;CSCO;GILD;HD;JNPR;TWC;FRX;MS;SYMC;ROC;PRGO;F;SI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
April 8, 2015
12:17 EDTPRGOOn The Fly: Midday Wrap
Subscribe for More Information
11:51 EDTPRGOPerrigo calls active on Mylan proposal to acquire for $205 per share
Subscribe for More Information
11:45 EDTPRGOMylan volatility up after proposes to acquire Perrigo for $205 per share
Subscribe for More Information
11:40 EDTPRGOPerrigo up $47.10 to $211.81, trading above Mylan's $205/share proposal
Subscribe for More Information
11:35 EDTPRGOGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
Subscribe for More Information
11:34 EDTPRGOGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
11:32 EDTPRGOMylan proposes to acquire Perrigo for $205 per share
Subscribe for More Information
11:31 EDTPRGOPerrigo halted for volatility after jumping 7% to $176.42
Subscribe for More Information
11:29 EDTPRGOMylan proposes to acquire Perrigo for $205 per share
Subscribe for More Information
11:08 EDTSYMCCybersecurity stocks in focus after White House security breach
Subscribe for More Information
09:36 EDTSYMCSingtel acquires cybersecurity company Trustwave for $810M
Subscribe for More Information
08:56 EDTPRGOPerrigo's ANDA for equivalent of Mallinckrodt's Exalgo approved by FDA
Subscribe for More Information
April 7, 2015
19:54 EDTCSCOCisco, American Express invest in mobile wallet startup, Economic Times says
Subscribe for More Information
17:58 EDTGILDGilead submits NDA for investigational combination for treatment of HIV-1
Subscribe for More Information
16:00 EDTGILDOptions Update; April 7, 2015
Subscribe for More Information
08:11 EDTMSGoldman Sachs, Morgan Stanley estimates raised at Susquehanna
Susquehanna raised its estimates for both Goldman Sachs (GS) and Morgan Stanley (MS) to reflect a strong quarter for FICC driven by interest rate and currency volatility and more stable credit markets as well as better I&L. Susquehanna maintains Neutral ratings on both Goldman Sachs and Morgan Stanley shares.
April 6, 2015
07:36 EDTGILDGilead Q1 HCV revenue poised to beat expectations, says RBC Capital
After analyzing weekly prescription data, RBC Capital believes that Gilead's weekly hepatitis C prescriptions are tracking towards $3.5B-$3.6B of revenue from hepatitis C drugs for Q1, versus the consensus outlook of about $2.6B. The firm keeps an Outperform rating on Gilead.
06:07 EDTCSCO, JNPRSpherix issues update on several matters
Subscribe for More Information
April 5, 2015
15:52 EDTFNHTSA to reopen investigation into Ford sedan exterior lighting failures
Subscribe for More Information
14:43 EDTGILDActavis seeks FDA approval to market generic version of Gilead's Letairis
Actavis (ACT) on Friday, confirmed that it has filed an Abbreviated New Drug Application with the FDA seeking approval to market Ambrisentan Tablets, 5 mg and 10 mg. Actavis' ANDA product is a generic version of Gilead Science's (GILD) Letairis, which is a treatment for pulmonary arterial hypertension. Gilead Sciences and Royalty Pharma Collection Trust filed suit against Actavis on April 1, in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of U.S. Patent number RE42,462. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities. Based on available information, Actavis believes it may be a "first applicant" to file an ANDA for the generic version of Letairis and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity. For the 12 months ending December 31, Letairis had global sales of approximately $595M, according to Gilead.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use